Pharmacological effects of primaquine ureas and semicarbazides on the central nervous system in mice and antimalarial activity in vitro.

Author: FideckaSylwia, KaiserMarcel, KedzierskaEwa, KneževićDanijel, OrzelskaJolanta, PerkovićIvana, ZorcBranka

Paper Details 
Original Abstract of the Article :
New primaquine (PQ) urea and semicarbazide derivatives 1-4 were screened for the first time for central nervous system (CNS) and antimalarial activity. Behavioural tests were performed on mice. In vitro cytotoxicity on L-6 cells and activity against erythrocytic stages of Plasmodium falciparum was d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/fcp.12161

データ提供:米国国立医学図書館(NLM)

Primaquine Derivatives: Exploring New Avenues for Antimalarial Therapy

Malaria, a life-threatening disease caused by parasites transmitted through mosquito bites, continues to pose a significant global health challenge. This research investigates the potential of new primaquine (PQ) urea and semicarbazide derivatives as potential antimalarial agents. The authors screened these compounds for their effects on the central nervous system (CNS) in mice and their activity against the erythrocytic stages of Plasmodium falciparum, the parasite responsible for malaria. They identified promising candidates, particularly compound 4, which exhibited potent antimalarial activity in vitro and also displayed CNS activity, suggesting potential applications beyond malaria treatment. The study highlights the potential of these derivatives as lead compounds for the development of new drugs targeting both the CNS and malaria parasites.

New Hope in the Fight Against Malaria

This study offers promising leads for the development of new antimalarial drugs, particularly compound 4, which exhibited significant activity against Plasmodium falciparum. The findings underscore the potential of these derivatives to contribute to the ongoing battle against malaria.

A Desert of Challenges, a Oasis of Innovation

The fight against malaria is a relentless journey, much like traversing a vast desert. This study offers a glimmer of hope, highlighting the potential of new drug candidates to offer relief from this devastating disease.

Dr.Camel's Conclusion

This study explores the potential of novel primaquine derivatives as promising candidates for antimalarial therapy, offering new avenues for combatting this global health threat. The identification of compound 4 as a potential lead compound with both antimalarial and CNS activity adds a layer of intrigue to this research, suggesting potential applications beyond malaria treatment. Remember, the journey to conquer malaria requires continuous innovation and relentless exploration.

Date :
  1. Date Completed 2016-10-17
  2. Date Revised 2016-12-30
Further Info :

Pubmed ID

26501210

DOI: Digital Object Identifier

10.1111/fcp.12161

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.